Retired Compendial Notices

Retired Compendial Notices: 2020-2024

<7> Labeling (posted 27–Mar–2020)
General Chapter <17> Prescription Container Labeling (posted 25–Oct–2019)
<90> Fetal Bovine Serum Quality Attributes and Functionality Notice of Intent to Revise (posted 05–Feb–2021)
<210> Monosaccharide Analysis (posted 22–Nov–2019)
<411> Folic Acid Assay and Folic Acid Tablets Notice of Intent to Revise (posted 22–Apr–2022)
<661.1> Plastic Materials of Construction Notice of Intent to Revise (posted 18–Dec–2020)
<661.2> Plastic Packaging Systems for Pharmaceutical Use Notice of Intent to Revise (posted 16-Dec-2022)
<665> Plastic Components and Systems Used to Manufacture Pharmaceutical Drug Products and Biopharmaceutical Drug Substances and Products Notice of Intent to Revise (posted 25–Feb–2022)
<668> Cured Silicone Elastomers for Pharmaceutical Manufacturing and Packaging Components Notice of Intent to Revise (posted 26–Dec–2019)
<795> Pharmaceutical Compounding—Nonsterile Preparations Notice of Intent to Revise (posted 01–Sep–2021)
<797> Pharmaceutical Compounding— Sterile Preparations Notice of Intent to Revise (posted 01–Sep–2021)
<711> Dissolution Notice of Intent to Revise (posted 29–Oct–2021)
<711> Dissolution (posted 27–May–2022)
<800> Hazardous Drugs—Handling in Healthcare Settings (posted 01–May–2020)
<825> Radiopharmaceuticals- Preparation, Compounding, Dispensing, and Repackaging Notice of Intent to Revise (posted 27-Oct-2023)
<1085.1> Use of Recombinant Reagents in the Bacterial Endotoxins Test: Comments Received from Stakeholders (posted 18–Nov–2020; updated 11–Dec–2020)
<1085.1> Use of Recombinant Reagents in the Bacterial Endotoxins Test: Comments Received from Stakeholders (posted 18–Nov–2020; updated 11–Dec–2020)
<1059> Excipient Performance (posted 10–Dec–2019)
Abiraterone Acetate Tablets Pending Notice of Intent to Revise (posted 25–Jan–2019)
Accelerated Revisions: Format Change (posted 29–May–2020)
Acyclovir Notice of Intent to Revise (posted 25–Feb–2022)
Acyclovir Notice of Intent to Revise (posted 16-Dec-2022)
Albuterol Inhalation Solution Notice of Intent to Revise (posted 16–Apr–2021)
Alcohol, Dehydrated Alcohol (posted 31–Jul–2020)
Amantadine Hydrochloride Notice of Intent to Revise (posted 27–May–2020)
Aminocaproic Acid Oral Solution Notice of Intent to Revise (posted 31–Jul–2020)
Amitriptyline Hydrochloride Tablets (posted 29–Oct–2021)
Ampicillin Capsules Pending Revision Notice (posted 24-Feb-2023)
Aprepitant Capsules, Galantamine Tablets, Praziquantel Tablets, and <1092> The Dissolution Procedure: Development and Validation Notice of Intent to Revise (posted 28–Aug–2020)
Aprotinin and Aprotinin Injection Monographs (posted 24–Apr–2020)
Atorvastatin Calcium Tablets Pending Monograph Proposal (posted 26-May-2023)
Azeotropic Isopropyl Alcohol Notice of Intent to Revise (posted 30–Apr–2021)Bacterial Endotoxin Test (BET): A USP Comparability Study of Recombinant Reagents (Recombinant Factor C and Recombinant Cascade) to Lysate Reagents (LAL) (posted 25–Jun–2021)
Baclofen Injection Notice of Intent to Revise (posted 30–Apr–2021)
Benztropine Mesylate Notice of Intent to Revise (posted 28–Dec–2020)
Benztropine Mesylate Notice of Intent to Revise (posted 30–Apr–2021)
Bicalutamide Tablets Notice of Intent to Revise (posted 16-Dec-2022)
Bifidobacterium bifidium Notice of Intenet to Revise (posted 27–Aug–2021)
Bifidobacterium longum subsp. longum Notice of Intent to Revise (posted 27–Aug–2021)
Bupropion Hydrochloride Notice of Intent to Revise (posted 19–Feb–2021)
Bupropion Hydrochloride Extended-Release Tablets Pending Revision Notice (posted 26–Dec–2019)
Castor Oil Notice of Intent to Revise (posted 31–Jul–2020)
Carbamazepine Extended-Release Tablets (posted 27-Oct-2023)
Carbamazepine Tablets (posted 26–Feb–2021)
Carbomer 934, Carbomer 934P, Carbomer 941, and Carbomer 1342 Notice of Intent to Revise (posted 18-Nov-2022)
Cetyl Alcohol (posted 28–Feb–2020)
Changes to General Chapter Format and General Chapter Reference Format (posted 31–Jul–2015)
Changes to USP's Description and Solubility Reference Table (posted 30-Sep-2022)
Chapters Affected by Revision to <381> Elastomeric Closures for Injections (posted 22–May–2020)
Chapters Affected by Revision to <1079> Risks and Mitigations Strategies for the Storage and Transportation of Finished Drug Products (posted 22–May–2020)
Chapters Affected by Revision to <1087> Apparent Intrinsic Dissolution—Dissolution Testing Procedures for Rotating Disk and Stationary Disk (posted 22–May–2020)
Chymotrypsin and Chymotrypsin for Ophthalmic Solution Monographs (posted 10–Apr–2020)
Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules Pending Notice of Intent to Revise (posted 30–Jul–2021)
Chlorpromazine Hydrochloride Tablets (posted 31–Jul–2020)
Chlorpromazine Hydrochloride Oral Concentrate Pending Notice of Intent to Revise (posted 18–Dec–2020)
Clean-up of General Chapter References in USP 39–NF 34 (posted 31–Jul–2015; updated 28–Aug–2015)
Clean-up of General Chapter References in USP 40–NF 35 (posted 28–Oct–2016)
Clomipramine Hydrochloride Capsules (posted 29–May–2020)
Clonidine Transdermal System Notice of Intent to Revise (posted 27–Mar–2020)
Codeine Phosphate Notice of Intent to Revise (posted 26–Mar–2021)
Comment Deadline Extended: Pharmacopeial Forum 46(3) (posted 15–Jun–2020)
Comment Deadline Extended—Reporting Threshold in USP–NF Monographs: Proposed Policy Change for Public Comment (posted 07–Nov–2019) | En español
Comments Received from Stakeholders: Reporting Thresholds in USP–NF Monographs (posted 28–Feb–2020)
Compounding Compendium (posted 31–May–2019)
Copovidone Notice of Intent to Revise (posted 30–Apr–2021)
Cranberry Fruit Juice Dry Extract Notice of Intent to Revise (posted 30–Dec–2021)
Deferred Proposal: General Notices and Requirements, 5.60.40 Impurities that are Unusually Toxic and/or Mutagenic (posted 30–Sep–2020)
Desmopressin Acetate (posted 30–Apr–2020)
Dextran 40 Notice of Intent to Revise (posted 30–Jul–2021)
Dextran 70 Notice of Intent to Revise (posted 30–Jul–2021)
Dextrose Injection Notice of Intent to Revise (posted 15–Oct–2021)
Dextrose Injection Notice of Intent to Revise (posted 25–Feb–2022)
Dexamethasone Tablets Notice of Intent to Revise (posted 30–Jul–2021)
Dexamethasone Tablets Pending Monograph Notice (posted 27-Jan-2023)
Diatrizoate Meglumine and Diatrizoate Sodium Solution Pending Notice of Intent to Revise (posted 26–Mar–2021)
Diclofenac Potassium for Oral Solution Pending Revision Notice (posted 25–Feb–2022)
Diclofenac Sodium and Misoprostol Delayed-Release Tablets Pending Monograph Revision (posted 29–Mar–2019)
Diphenhydramine Hydrochloride Oral Powder Notice of Intent to Revise (posted 25–Sep–2020)Divalproex Sodium Extended-Release Tablets (posted 29–Mar–2019)
Dipivefrin Hydrochloride (posted 30–Apr–2020)
Divalproex Sodium Extended-Release Tablets Pending Notice of Intent to Revise (posted 19–Nov–2021)
Esomeprazole Magnesium Pending Revision Notice (posted 29-Jul-2022)
Expanded Monograph Omission Initiative (posted 17–Nov–2017)
Extended Implementation and Comment Period Extension for USP and FCC Publications (posted 27–Mar–2020; updated 31–Mar–2020; updated 24–Apr–2020) | En español
Extended Phenytoin Sodium Capsules Pending Notice of Intent to Revise (posted 26–Apr–2019)
FDA Resources for Angiotensis II Receptor Blockers Voluntary Recall (posted 30–Aug–2019)
Filgrastim (posted 10–Apr–2020)
Fluphenazine Hydrochloride Tablets (posted 24–Apr–2020)
Fondaparinux Sodium Notice of Intent to Revise (posted 30–Dec–2021)
Fosamprenavir Calcium Notice of Intent to Revise (posted 18-Nov-2022)
Fosfomycin Tromethamine (posted 05-Oct-2022)
Gemfibrozil Tablets Notice of Intent to Revise (posted 28–Aug–2020)
Glucagon Notice of Intent to Revise (posted 01–Oct–2021)
Gramicidin Notice of Intent to Revise (posted 21–Jan–2022)
Guanfacine Tablets Pending Revision Notice (posted 28-Apr-2023)
Glycine- Status Update (posted 05–Dec–2019)
Hydroxyurea Capsules Pending Revision Notice (posted 29-Dec-2023)
Ioversol (posted 28–Aug–2020)
Ioversol Injection (posted 28–Aug–2020)
Ioxilan Notice of Intent to Revise (posted 09-Aug-2022)
Inhalation Product Monographs: Removal of Performance Tests (posted 25–Jun–2021)
Ipratropium Bromide Inhalation Solution (posted 28–May–2021)
Iron Dextran Injection Pending Monograph Notice (posted 28-Apr-2023)
Isopropyl Alcohol Notice of Intent to Revise (posted 30–Apr–2021)
Isotretinoin Capsules Notice of Intent to Revise (posted 27-May-2022)
Lacosamide Oral Solution Pending Revision Notice (posted 25–Feb–2022)
Lactobacillus reuteri Notice of Intent to Revise (posted 27–Aug–2021)
Lacotbacillus rhamnosus Notice of Intent to Revise (posted 27–Aug–2021)
Lactobacillus rhamnosus Notice of Intent to Revise (posted 20–Nov–2020)
Lauroyl Polyoxyglycerides Notice of Intent to Revise (posted 19–Feb–2021)
Lauroyl Polyoxylglycerides Notice of Intent to Revise (posted 19–Feb–2021)
Levalbuterol Hydrochloride (posted 22–Apr–2022)
Levalbuterol Inhalation Solution (posted 22–Apr–2022)
Levothyroxine Sodium Tablets (posted 24–Apr–2020)
Levetiracetam Tablets Pending Notice of Intent to Revise (posted 25–Jun–2021)
List of monographs appearing in redesigned format as of USP 43-NF 38 1S (posted 21-Feb-2020)
List of monographs appearing in redesigned format as of USP 43-NF 38 (posted 01-Nov-2019)
List of monographs appearing in redesigned format as of USP 42-NF 37 2S (posted 31-May-2019)
List of monographs appearing in redesigned format as of USP 42-NF 37 1S (posted 25-Jan-2019)
List of monographs appearing in redesigned format as of USP 42-NF 37 (posted 26–Oct–2018)
List of monographs appearing in redesigned format as of USP 41–NF 36 2S (posted 18–Jun–2018)
List of monographs appearing in redesigned format as of USP 41–NF 36 1S (posted 26–Jan–2018)
List of monographs appearing in redesigned format as of USP 41–NF 36 (posted 27–October–2017)
Lithium Oral Solution Pending Revision Notice (posted 17-Nov-2023)
Loperamide Hydrochloride Notice of Intent to Revise (posted 27–Mar–2020)
Loperamide Hydrochloride Notice of Intent to Revise (posted 24–Apr–2020)
Magnesium Family of Monographs Notice of Intent to Revise (posted 27–Aug–2021)
Magnesium Hydroxide and Magnesium Hydroxide Paste Notice of Intent to Revise (posted 30–Jul–2021)
Magnesium Sulfate Notice of Intent to Revise (posted 30–Dec–2021)
Mesalamine Delayed-Release Tablets Notice of Intent to Revise (posted 30–Jul–2021)
Metformin Hydrochloride Extended-Release Tablets (posted 25–Oct–2019)
Metformin Hydrochloride Extended-Release Tablets Pending Notice of Intent to Revise (posted 28–May–2021)
Metformin Hydrochloride Extended-Release Tablets Pending Notice of Intent to Revise (posted 31–Jan–2020)
Methyldopate Hydrochloride and Methyldopate Hydrochloride Injection (posted 23–Oct–2020)
Methylene Blue Pending Revision Notice (posted 30-Jun-2023)
Methylprednisolone Sodium Succinate for Injection Notice of Intent to Revise (posted 28–May–2021)
Metolazone Tablet Pending Notice of Intent to Revise (posted 18–Dec–2020)
Metoprolol Succinate Extended-Release Tablets Pending Revision Notice (posted 30–Apr–2021)
Metyrosine (posted 24–Apr–2020)
Metyrosine Capsules (posted 31–Jul–2020)
Midodrine Hydrochloride Tablets Pending Revision Notice (posted 18-Nov-2022)
Minocycline Hydrochloride Extended-Release Tablets Pending Revision Notice (posted 29–Mar–2019)
Mitotane Notice of Intent to Revise (posted 21–Apr–2022)
Mitotane Tablets Notice of Intent to Revise (posted 21–Apr–2022)
Monograph and Reference Standard Nomenclature Update for Glyceryl Monocaprylocaprate and Glyceryl Mono and Dicaprylocaprate (posted 24–Apr–2020; updated 26–Jun–2020)
Monographs and GCs Affected by Revision to GC <1> Injections (posted 31–Jul–2015)
Monographs Affected by Revision to <7> Labeling (posted 05–Oct–2018)
Monographs Affected by Revision to <11> USP Reference Standards (posted 26-Dec–2019)
Monographs Affected by Revision to <126> Somatropin Bioidentity Tests (posted 30-Sep-2022)
Monographs Affected by Revision to <161> Medical Devices— Bacterial Endotoxin and Pyrogen Tests (posted 05–Oct–2018)
Monographs Affected by Revision to General Chapter <191> Identification Tests – General (posted 16–Mar–2015)
Monographs Affected by Revision to <191> Identification Tests– General (posted 27–Oct–2017)
Monographs Affected by Revision to <197> Spectroscopic Identification Test (posted 04–Oct–2019) | En español
Monographs and GCs Affected by Revisions to GC <231> Heavy Metals Revision Bulletin (posted 27–Mar–2015; official 01–Apr–2015; updated 12–May–2015)
Monographs Affected by Revision to Revision to <345> Assay for Citric Acid/Citrate and Phosphate (posted 27–Oct–2017)
Monograph Affected by the Revision of <531> Thiamine Assay (posted 28–Oct–2016)
Monographs Affected by Revision to <561> Articles of Botanical Origin (posted 04–Oct–2019)
Monographs Affected by Revision to <591> Zinc Determination (posted 27–Oct–2017)
Monographs Affected by Revision to <591> Zinc Determination (posted 04–Oct–2019)
Monographs Affected by Revision to <659> Packaging and Storage (posted 28–Oct–2016)
Monographs and GCs Affected by Revisions to GC <601> (posted 25–Apr–2014)
Monographs and GCs Affected by Revision to General Chapter <659> Packaging and Storage Requirements (posted 24–Apr–2015)
Monographs Affected by Revision to <659> Packaging and Storage (posted 28–Oct–2016)
Monographs and GCs Affected by Revision to GC <661> Containers—Plastics (posted 31–Jul–2015)
Monographs Affected by Revision to <795> Pharmaceutical Compounding- Nonsterile Preparations (posted 01-Nov-2022)
Monographs Affected by Revision to <797> Pharmaceutical Compounding- Sterile Preparations (posted 01-Nov-2022)
Monographs with Postponed Content (posted 30–Jul–2021)
Naloxone Hydrochloride Notice of Intent to Revise (posted 30-Sep-2022)
Monographs Affected by Revision to <821> Radioactivity (posted 28–Oct–2016)
Monographs Affected by Revision to <855> Mephelometry, Turbidity, and Visual Comparison (posted 05–Oct–2018)
Monographs Affected by Revision to <1046> Cellular and Tissue-Based Product (posted 04–Oct–2019)
Monographs Affected by Revision to <1090> Assessment of Solid Oral Drug Product Performance and Interchangeability, Bioavailability, Bioequivalence, and Dissolution (posted 05–Oct–2018)
Monographs Affected by Revision to <1119> Near-Infrared Spectroscopy [New <1856> Near-Infrared Spectroscopy–Theory and Practice] (posted 04–Oct–2019)
Monographs Affected by Revision to <1211> Sterility Assurance (posted 27–Oct–2017)
Monographs and General Chapters Affected by Revision to General Notices (posted 27–Oct–2017)
Monographs Affected by Revision to <1119> Near-Infrared Spectroscopy [New <1856> Near-Infrared Spectroscopy–Theory and Practice] (posted 04–Oct–2019)
Monographs Affected by Revision to <1120> Raman Spectroscopy (New: <1858> Raman Spectroscopy—Theory and Practice) (posted 26–Dec–2019)
Monographs Affected by Revision to <1136> Packaging and Repackaging—Single Unit Containers (posted 04–Oct–2019)
Monographs Affected by Revision to <1177> Good Packaging Practices (posted 04–Oct–2019)
Monograph Affected by Revision to <1195> Significant Change Guide for Bulk Pharmaceutical Excipients (posted 02–Oct–2020)
Monographs Affected by Revision to <1661> Evaluation of Plastic Packaging Systems for Pharmaceutical Use and Their Materials of Construction (posted 26–Dec–2019)
Monographs Affected by Revision to <1788> Methods for the Determination of Particulate Matter in Injections and Ophthalmic Solutions (posted 02–Oct–2020)
New Revision Markup for Reference Changes in USP–NF (posted 25–Jul–2014)
Nicardipine Hydrochloride Injection (posted 26–Oct–2018)
Nicardipine Hydrochloride Injection (posted 28-Apr-2023)
Olmesartan Medoxomil Tablets Pending Revision Notice (posted 26–Jul–2019)
Orlistat Notices of Intent to Revise (posted 28–May–2021)
Orlistat Capsules Notice of Intent to Revise (posted 28–May–2021)
Oxcarbazepine Oral Suspension Pending Notice of Intent to Revise (posted 25–Jun–2021)
Oxcarbazepine Oral Suspension Pending Revision Notice (posted 26-Apr-2024)
Parachlorophenol (posted 15–Apr–2020)
Paroxetine Hydrochloride (posted 02–Jan–2020)
Pemetrexed Disodium (posted 29–Jan–2021)
PF Online: Changes to Briefings (posted 02–Jan–2020)
Phenelzine Sulfate Notice of Intent to Revise (posted 29-Apr-2022)
Phenoxybenzamine Notice of Intent to Revise (posted 16-Dec-2022)
Pilocarpine (posted 30–Aug–2019)
Prazosin Hydrochloride Notice of Intent to Revise (posted 03–Jan–2022)
Prazosin Hydrochloride Capsules Notice of Intent to Revise (posted 24-Feb-2023)
Prednisone Tablets (posted 30–Aug–2019)
Prochlorperazine Maleate Tablets (posted 26-Aug-2022)
Propafenone Hydrochloride Extended-Release Capsules (posted 27‒Apr‒2018)
Propafenone Hydrochloride Extended-Release Capsules (posted 24–Apr–2020)
Pyrazinamide Notice of Intent to Revise (posted 19–Feb–2021)
Quinidine Gluconate Extended-Release Tablets Pending Notice of Intent to Revise (posted 26–Feb–2021)
Reporting Threshold in USP–NF Monographs: Proposed Policy Change for Public Comment (posted 13–Aug–2019; comment deadline 12–Nov–2019)
Restoration of Display of USAN Adoption Dates (posted 12–Feb–20)
Revisions to Containers for Dispensing Capsules and Tablets (posted 01–Nov–2019)
Ribose (posted 26–Jun–2020)
Rotigotine Notice of Intent to Revise (posted 30–Jul–2021)
Rufinamide Tablets (posted 28–Feb–2020)
Standards Affected by Postponements of <795> Pharmaceutical Compounding— Nonsterile Preparations, <797> Pharmaceutical Compounding— Sterile Preparations, and <825> Radiopharmaceuticals— Preparation, Compounding, Dispensing, and Repackaging (posted 03–Feb–2020)
Standards Affected by Appeals to <795> Pharmaceutical Compounding — Nonsterile Preparations, <797> Pharmaceutical Compounding — Sterile Preparations, and <825> Radiopharmaceuticals – Preparation, Compounding, Dispensing, and Repackaging (posted 24–Apr–2020)
Quetiapine Extended-Release Tablets Pending Revision Notice (posted 31–Dec–2021)
Stearyl Alcohol (posted 28–Feb–2020)
Sucrose Notice of Intent to Revise (posted 26–Feb–2021; updated 02–Apr–2021; updated 18–Jun–2021)
Sulfamethoxazole (posted 12–Jun–2020)
Tacrolimus Capsules Pending Revision Notice (posted 20–Nov–2020)
Talc Notice of Intent to Revise (updated 18–Dec–2020)
Technetium Tc 99m Monographs: Removal of Biological Tests (posted 30–Jul–2021)
Telmisartan and Amlodipine Tablets (posted 28–Feb–2020; updated 28–Aug–2020)
Teriparatide Injection Pending Revision Notice (posted 29–May–2020)
Tetracycline, Tetracycline Hydrochloride and Tetracycline Hydrochloride Capsules Notice of Intent to Revise (posted 18–Dec–2020)
Tobramycin Sulfate Pending Revision Notice (posted 28-Oct-2022)
Triamcinolone Acetonide Nasal Spray (posted 26–Jun–2020)
Doxycycline Hyclate Tablets Pending Revision Notice (posted 26-Aug-2022)
Upcoming Changes to USP's Description and Relative Solubility Reference Table (posted 24-Jun-2022)
Update on the Delayed Implementation of <661.1> and <661.2> (posted 26–Dec–2019)
Update of Hydroxycloroquine Sulfate Monograph (posted 19–May–2020)
Update: Reporting Thresholds in USP–NF Monographs (posted 23–Jul–2020)
USP 43–NF 38— Last Print Edition (posted 04–Oct–2019)
USP–NF Online: Official Date Correction to Mandelic Acid, Methylpyrrolidone, Monosodium Glutamate, and Colorimetric Solutions Introduction (posted 05–Apr–2019)
USP–NF Online: Official Status Correction to Anhydrous Dibasic Calcium Phosphate (posted 28–Feb–2020)
USP–NF Online: Official Status Correction to Desoxychloic Acid and Fluconazole Injection (posted 02–Aug–2019)
USP–NF Online: Official Status Correction to Eriochrome Black T (posted 30–Aug–2019)
USP–NF Online: Official Status Correction to Manganese Sulfate Injection (posted 27–Mar–2020)
USP–NF Online: Official Status Correction to Purified Stearic Acid (posted 27–Mar–2020)
USP–NF Online: Official Status Correction to Talc, Chlorhexidine Gluconate Oral Rinse, and Powdered Echinacea purpurea (posted 15–Nov–2019)
USP–NF Online: Upcoming Planned Changes to Title and Format (posted 27–Mar–2020; updated 29–May–2020) | En español
USP Provides Guidance on the Use of Recombinant Reagents for Bacterial Endotoxin Test (posted 29–May–2020; updated 30–Jul–2020)
Vancomycin Injection Notice of Intent to Revise (posted 25–Mar–2022)
Ziprasidone Hydrochloride Notice of Intent to Revise (posted 27-May-2022)

Retired Compendial Notices: 2015-2019

<1> Injections and Implanted Drug Products (Parenterals)—Product Quality Tests (posted 26–Feb–2016)
<7> Labeling (posted 25–Jan–2019)
<7> Labeling (posted 26–Apr–2019)
<87> Biological Reactivity, In Vitro (posted 30–Jan–2015; updated 27–Feb–2015)
<87> Biological Reactivity, In Vitro, <88> Biological Reactivity, In Vivo, and <1031> The Biocompatibility of Materials used in Drug Containers, Medical Devices and Implants (posted 30–Dec–2016; deadline 30–Jan–2017)
<191> Identification Tests— General (posted 27–Jul–2018)
<231> Heavy Metals and Affected Monographs and General Chapters (posted 14–Jan–2015)
<381> Elastomeric Closure for Injections (posted 30–Dec–2016; deadline 30–Jan–2017)
<382> Elastomeric Closure Functionality in Injectable Pharmaceutical Packaging/Delivery Systems (posted 30–Dec–2016; deadline 30–Jan–2017)
<467> Residual Solvents (posted 22–Feb–2019)
<467> Residual Solvents (posted 02–Aug–2019)
<476> Organic Impurities and <1086> Impurities in Drug Substances and Drug Products (posted 29‒Sep‒2017)
<541> Titimetry (posted 29‒Sep‒2017)
<561> Articles of Botanical Origin (posted 30–Jun–2017)
<659> Packaging and Storage Requirements (posted 31–Mar–2017)
<661> Plastic Packaging Systems and Their Materials of Construction (posted 31–Mar–2017)
<661.1> Plastic Materials of Construction (posted 31–Mar–2017)
<661.2> Plastic Packaging Systems for Pharmaceutical Use (posted 31–Mar–2017)
<662> Metal Packaging Components and their Materials of Construction (posted 26–Feb–2016; deadline 29–Mar–2016)
<795> Pharmaceutical Compounding– Nonsterile Preparations (posted 30–Mar–2018)
<797> Pharmaceutical Compounding—Sterile Preparations to be Republished in Pharmacopeial Forum for Public Comment (posted 27–Jan–2017)
<797> Pharmaceutical Compounding—Sterile Preparations (posted 25–Sep–2015)
<797> Pharmaceutical Compounding— Sterile Preparations (posted 27–Jul–2018)
<800> Hazardous Drugs—Handling in Healthcare Settings (15–Apr–2016; updated 29–Apr–2016)
<800> Hazardous Drugs‒ Handling in Healthcare Settings (posted 29‒Sep‒2017)
<825> Compounding—Radiopharmaceuticals (posted 01–Jun–2017)
<825> Radiopharmaceuticals— Preparation, Compounding, Dispensing, and Repackaging (posted 27–Jul–2018)
<922> Water Activity (posted 30–Mar–2018)
<1079.1> Storage and Transportation of Investigational Drug Products (posted 26–Feb–2016; deadline 29–Mar–2016)
<1085> Guidelines on Endotoxins Test (posted 26–Jan–2018)
<1153> Drug Products Containing Nanomaterials (posted 26–Apr–2019)
<1168> Compounding for Phase I Investigational Studies (posted 28‒Apr‒2017)
<1236> Solubility Measurements (posted 30–Sep–2016; deadline 30–Oct–2016)
<1381> Evaluation of Elastomeric Components Used in Pharmaceutical Packaging/Delivery Systems (posted 30–Dec–2016; deadline 30–Jan–2017)
<1382> Assessment of Elastomeric Closure Functionality in Injectable Pharmaceutical Packaging/Delivery Systems (posted 30–Dec–2016; deadline 30–Jan–2017)
<1711> Oral Solid Dosage Forms - Dissolution Testing (posted 29‒Sep‒2017)
<1788> Methods for the Determination of Particulate Matter in Injections and Ophthalmic Solutions (posted 30–Mar–2018)
<2740> Manufacturing Practices for Dietary Ingredients (posted 29‒Sep‒2017)
<2750> Manufacturing Practices for Dietary Supplements (posted 29‒Sep‒2017)
Acetaminophen Oral Suspension (posted 29–Jun–2018)
Acetaminophen Tablets (posted 29–Jun–2018)
Addition of UNII Codes in USP 40–NF 35 Online (posted 28–Oct–2016)
Allupurinol (posted 17–Apr–2015)
Almotriptan Malate (posted 08–Jul–2016; updated 26–Aug–2016)
Alprazolam Tablets (posted 22–Feb–2019)
Aminocaproic Acid Tablets (posted 31–May–2019)
Amoxicillin Capsules (posted 30–Mar–2018)
Amoxicillin Tablets (posted 30–Mar–2018)
Aspartic Acid (posted 18–Dec–2015)
Aspirin Boluses (posted 29–Apr–2016)
Aspirin Monographs (posted 29–Apr–2016)
Atropine Sulfate Ophthalmic Ointment (posted 31–Aug–2018; retracted 04–Sep–2018)
Atropine Sulfate Ophthalmic Solution (posted 04–Sep–2018)
Cell Banking (posted 29–Jul–2016; deadline 29–Aug–2016)
Changes to General Chapter Format and General Chapter Reference Format (posted 31–Jul–2015)
Change to USP–NF Revision Mark-Up (posted 05–Oct–2018)
Changes to Pending Monographs Program (posted 29–May–2015)
Cidofovir (posted 04–Mar–2019)
Clarithromycin (posted 17–Apr–2015; updated 26–Jun–2015)
Clarithromycin Tablets (posted 17–Apr–2015; updated 26–Jun–2015)
Clindamycin Phosphate (posted 24‒Feb‒2017)
Clomipramine Hydrochloride Capsules (posted 28‒Jul‒2017)
Cloxacillin Sodium (posted 26–Feb–2016)
Cloxacillin Sodium Intramammary Infusion (posted 23–Feb–2018)
Comment Deadline Extended: Pharmacopeial Forum 44(6) and 45(1) (posted 30–Jan–2019)
Comment Deadline for Packaging General Chapters Appearing in Pharmacopeial Forum 43(3) Extended (posted 28‒Jul‒2017)
Comment Deadline for Pharmacopeial Forum 43(2) Extended (posted 23‒May‒2017, updated 18–Jul–2017)
Compounding Compendium (posted 31–May–2019)
Corticotropin (posted 18–Dec–2015)
Cumulative List of USP–NF Revision Now Available (posted 29–Jul–2016)
Dextromethorphan (posted 28–Feb–2014; updated 01–Dec–2016)
Dextromethorphan Hydrobromide (posted 28–Feb–2014; updated 01–Dec–2016)
Diclofenac Sodium and Misoprostol Delayed-Release Tablets (posted 28‒Jul‒2017)
Dicloxacillin Sodium (posted 26–Feb–2016)
Digoxin (posted 27–Feb–2015)
Diltiazem Hydrochloride Extended-Release Capsules (posted 29‒Sep‒2017)
Diltiazem Hydrochloride Extended-Release Capsules (Pending) (posted 25–May–2018)
Diphenhydramine Hydrochloride Monographs (posted 01–Feb–2016; updated 26–Feb–2016)
Doxorubicin Hydrochloride Injection (posted 26–Feb–2016)
Doxycycline Hyclate Tablets (posted 10‒Apr‒2017)
Doxycycline Hyclate Capsules (posted 10‒Apr‒2017)
Dydrogesterone (posted 31–May–2019)
Dutasteride (posted 26–Jun–2015)
Dutasteride (posted 26–Feb–2016)
Dutasteride (posted 29–Jul–2016; updated 01–Dec–2016)
Early Input Sought on Proposed Naturally Occurring Endoxtoxin (NOE) Reference Standard (posted 27–May–2016)
Eprinomectin (posted 30–Oct–2015; updated 29–Apr–2016)
Erythromycin Delayed-Release Tablets (posted 22–Feb–2019)
Evaluating Screening Technologies for Assessing Medicine Quality (posted 29–Dec–2017)
Expanded Monograph Omission Initiative (posted 17–Nov–2017)
Fentanyl (posted 26–Apr–2019)
Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets (posted 20–Jul–2018)
First Supplement to USP 39–NF 34 Online: Errata Icon for GC <661.1> (posted 27–May–2016)
Flumethasone Pivalate (posted 30–Aug–2019)
Formoterol Fumarate (posted 22–Feb–2019)
General Chapter Prospectus: <197> Spectroscopic Identification Tests (posted 25–Mar–2016; deadline 25–Apr–2016)
General Chapters <232> Elemental Impurities- Limits and <2232> Elemental Contaminants in Dietary Supplements Applicable as of January 1, 2018 (posted 17–Nov–2017)
General Chapter <381> Elastomeric Closure for Injections (posted 17–Nov–2017)
General Notices and Requirements (posted 29‒Sep‒2017)
General Notices: Section 5.60.30 Related to Elemental Impurities (14–Jan–2015)
General Notices and Requirements Nomenclature of Biologics Proposal Will be Deferred (posted 27–Apr–2018)
Glyceryl Tristearate (posted 30–Oct–2015)
Glycine (posted 01–Jun–2018)
Insulin Glargine (posted 26–Feb–2016)
Insulin Glargine Injection (posted 26–Feb–2016)
Iohexol (posted 31–May–2019)
Integration of Accelerated Revisions into USP–NF Online (posted 18–Jun–2018)
Isosorbide Mononitrate Extended-Release Tablets (posted 28–Sep–2018)
June 2016 and April 2016 USP–NF Errata Postings (posted 10–Jun–2016)
June 2016 USP–NF Errata Posting (posted 24–Jun–2016)
Ketoconazole (posted 17–Nov–2017)
Krill Oil (posted 28‒Apr‒2017)
Levocetirizine Dihydrochloride (posted 30–Dec–2016)
Levothyroxine Sodium Tablets (18–Dec–2015)
Liothyronine Sodium (posted 18–Dec–2015)
Menthol (posted 25–Mar–2015)
Metformin Hydrochloride Extended-Release Tablets (Pending) (posted 29–Jun–2018)
Metformin Hydrochloride Extended-Release Tablets Online Correction (posted 16–Nov–2018)
Metronidazole Gel (posted 26–May–2017; updated 25–Aug–2017)
Methocarbamol (posted 17–Apr–2015)
Methocarbamol Tablets (posted 17–Apr–2015)
Methylcobalamin (posted 31–Mar–2017)
Methylcobalamin Tablets (posted 31–Mar–2017)
Methylphenidate Hydrochloride Extended-Release Tablets (posted 26–Jun–2015)
Miconazole Nitrate (posted 07–Mar–2019)
Monographs Affected by Cross-References to Pesticide Residue Analysis in <561> Articles of Botanical Origin (posted 26–Oct–2018)
Monographs Affected by Revision to <7> Labeling (posted 05–Oct–2018)
Monographs Affected by Revision to <161> Medical Devices— Bacterial Endotoxin and Pyrogen Tests (posted 05–Oct–2018)
Monographs Affected by Revision to <561> Articles of Botanical Origin (posted 05–Oct–2018)
Monographs Affected by Revisions to <795> Pharmaceutical Compounding—Nonsterile Preparations and <797> Compounding—Sterile Preparations (posted 10–Jun–2019)
Monographs Affected by Revision to <855> Mephelometry, Turbidity, and Visual Comparison (posted 05–Oct–2018)
Monographs Affected by Revision to <1090> Assessment of Solid Oral Drug Product Performance and Interchangeability, Bioavailability, Bioequivalence, and Dissolution (posted 05–Oct–2018)
Monographs and General Chapters Published in the Second Supplement to USP 38–NF 33 (posted 01–Jun–2015)
Moxidectin (Pending) (posted 27–Apr–2018)
Naproxen Sodium and Pseudoephedrine Extended-Release Tablets (posted 01–Jun–2018; revised 04–Jun–2018)
New USP–NF Online: First and Second Supplement to USP 41–NF 36 Table of Contents (posted 29–Jun–2018)
New USP-NF Online Launch and Delayed Implementation for Second Supplement to USP41-NF36 (posted 15–May–2018)
New USP–NF Online, USP 41–NF 36 and Supplements: Cross-reference to Chromatography <621>, Thin-Layer Chromatography (posted 10–Aug–2018)
Nicotine Polacrilex (posted 10‒Apr‒2017)
Notice of Publication Error: USP 40‒NF 35 Second Supplement: Timolol Maleate (posted 30‒Jun‒2017)
Octyldodecanol (posted 26–Feb–2016; updated 29–Apr–2016)
Olmesartan Medoxomil Tablets (posted 25–Jan–2019)
Omega-3-Acid Ethyl Esters (posted 30–May–2014; updated 27–Feb–2015)
Omega-3-Acid Ethyl Esters Capsules (posted 30–May–2014; updated 27–Feb–2015)
Omission of Levodopa Capsules Monograph (posted 01–Aug–2018)
Packaging Chapters Published in PF 44 (3) [May–Jun. 2017] to be Cancelled and Redeveloped (posted 23–Feb–2018)
Penacillamine Capsules (posted 27‒Apr‒2018)
Pharmacopeial Forum 44(2) [Mar.–Apr. 2018] Phytonadione Compounded Oral Suspension and Pyridostigmine Bromide Extended-Release Tablets (posted 23–Mar–2018)
Pharmacopeial Forum 43(4) [Jul.–Aug. 2017]: Climbazole (posted 09–Nov–2017)
Pharmacopeial Forum 44(3) [May–Jun. 2018]: Eriochrome Black T (posted 6–Jul–2018)
Pharmacopeial Discussion Group Working Procedure Changes (posted 26–Jan–2018)
Phenylephrine Hydrochloride Monographs (posted 01–Feb–2016)
Phytonadione (posted 27–Jul–2018)
Phytonadione (posted 28–Dec–2018)
Pimozide (posted 26–Feb–2016)
Pimozide Tablets (posted 26–Feb–2016)
Piperacillin and Tazobactam for Injection (posted 17–Apr–2015; updated 26–Jun–2015)
Potassium Chloride Extended-Release Tablets (posted 28–Sep–2018)
Potassium Chloride Extended-Release Tablets (posted 26–Oct–2018)
Potassium Chloride Extended-Release Tablets (posted 27–Sep–2019)
Potassium Chloride Extended-Release Tablets (posted 22–Nov–2019)
Potassium Chloride Extended-Release Capsules (posted 31–May–2019)
Powdered Digitalis (posted 27–Feb–2015; updated 28–Aug–2015)
Promethazine Hydrochloride Oral Solution (posted 18–Nov–2016)
Protamine Sulfate Injection (posted 17–Apr–2015)
Publication Announcements for USP 41–NF 36: Reorganization of Content (posted 27–Oct–2017)
Publication Announcements for USP 39–NF 34 Online: Reorganization of Table of Contents (09–Oct-2015)
Pyridostigmine Bromide Tablets (posted 30–Dec–2016)
Reagent Cross References in USP–NF (posted 31–Jul–2015)
Reagent Cross References in USP–NF Project Continues (posted 25–Jan–2019)
Reporting Threshold in USP–NF Monographs: Proposed Policy Change for Public Comment (posted 13–Aug–2019; input deadline 12–Nov–2019)
Removal of 3D Chemical Structures in USP–NF Online (posted 28–Oct–2016)
Removal of UNII Codes in Excipient Monographs in USP 42–NF 37 Online (posted 31–Aug–2018)
Revision Bulletin Schedule Change (posted 29‒Sep‒2017)
Revisions to Elastomeric Components for Injections Chapters <381>, <382>, <1381>, and <1382> (posted 31–May–2019)
Revisions to Plastic Packaging Chapters <659>, <661>, <661.1>, <661.2>, and <1661> (posted 26–Oct–2018; updated 28–Dec–2018)
Revision of Selected Insulin Family Monographs (posted 27‒Apr‒2018)
Salix Species Bark (posted 30–Jun–2017)
Salix Species Bark Powder (posted 30–Jun–2017)
Salix Species Bark Dry Extract (posted 30–Jun–2017)
Second Supplement to USP 39–NF 34 Online: Greek Symbols (posted 24–Jun–2016)
Selamectin (31‒Mar‒2017)
Sodium Bicarbonate (posted 26–Jun–2015)
Stage 4 Harmonization [April 2018]: Methylcellulose (posted 01–Jun–2018)
Stimuli Article: The Advisability and Feasibility of Developing USP Standards for Medical Cannabis (posted 26–Feb–2016)
Stimuli Article- The Complexity of Setting Compendial Specifications for Excipient Composition and Impurities (posted 27‒Apr‒2018)
Stimuli to the Revision Process: Proposed New USP General Chapter: The Analytical Procedure Lifecycle <1220> (posted 14–Oct–2016)
Supplier Qualification by User of Upstream Supply Chain for Pharmaceutical Excipients (posted 30–Mar–2018)
Tablet Breaking Force <1217> (posted 26–Aug–2016, deadline 15–Oct–2016)
Tamsulosin Hydrochloride (posted 18–Dec–2015)
The Analytical Procedure Lifecycle (posted 24–Jun–2016; deadline 29–Jul–2016)
Theophylline Oral Solution (posted 18–Nov–2016)
Topiramate (posted 26–Aug–2016)
Using Mean Kinetic Temperature to Evaluate Temperature Excursions During Storage and Transportation (posted 26–Oct–2018)
USP 40–NF 35: General Chapter <191> Notice (posted 01–Jun–2017)
USP 42–NF 37 Print, Online, and Flash Drive: Salix Species Bark, Salix Species Bark Dry Extract, and Salix Species Bark Powder (posted 11–Dec–2018)
Trihexyphenidyl Hydrochloride Oral Solution (posted 04–May–2016)
Trihexyphenidyl Hydrochloride Extended-Release Capsules (posted 04–May–2016)
Update to Style for Latin Binomials for USP 40–NF 35 (posted 28–Oct–2016)
USAN 2016 (posted 19–Aug–2016)
USP 41–NF 36 Online Table of Contents: Admissions (posted 17–Nov–2017)
USP Compounding Compendium (posted 05–Feb–2016)
USP–NF Errata Table Correction (posted 04–Oct–2017)
USP Monographs Will No Longer Cite Reference Standards Required by a General Chapter as of USP 41–NF 36 (posted 18‒Nov‒2016)
USP–NF Online: <191> Identification Tests—General, Chloride (posted 20–Nov–2018)
USP–NF Online: Proposal for Changes to Title and Format (posted 14–Sep–2018)
USP–NF Online: Proposed Changes to Title and Format- Update (posted 25–Jan–2019)
USP to Pilot Process for Early Input on General Chapters (posted 26–Feb–2016)
USP–NF Revision Symbols (posted 23–Feb–2018)
Valine (posted 30–Dec–2016)
Vancomycin Injection (posted 26–Oct–2018)
Witch Hazel (posted 30–June–2017)
Withdrawal of Notice of Intent to Revise: Monographs and General Chapters Published in the Second Supplement to USP 38–NF 33 (posted 26–Jun–2015)

Retired Compendial Notices: 2010-2014

Retired Compendial Notices prior to 2010